FDA approves Eli Lilly’s GLP-1 pill, opening the next phase of the weight loss drug market

FDA Approves Eli Lilly's GLP-1 Pill

Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.

FDA Approves Obesity Pill From Eli Lilly

U.S. regulators on April 1 approved an obesity pill called Foundayo from Eli Lilly, adding a second option for consumers who want to take weight loss drugs but desire to avoid injections. Foundayo is a glucagon-like peptide-1 (GLP-1) medication meant to be taken once a day. “We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications,” David Ricks, chair an…

Eli Lilly wins approval for new weight-loss pill. What to know.

Eli Lilly's new weight-loss pill, sold under the name Foundayo, gives consumers a second option for a non-injectable GLP-1.

FDA approves orforglipron, an oral GLP-1, for adults with obesity

The FDA approved a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related comorbidities, Eli Lilly announced.

Another GLP-1 weight loss pill gets FDA approval, and it has fewer restrictions on how it's used

The FDA approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing arsenal of obesity therapies.